Comparative Pharmacology
Head-to-head clinical analysis: LAMPRENE versus PYRAZINAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMPRENE versus PYRAZINAMIDE.
LAMPRENE vs PYRAZINAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clofazimine binds preferentially to mycobacterial DNA, inhibiting replication and exerting antimicrobial activity. It also has anti-inflammatory properties by modulating immune responses.
Converted to pyrazinoic acid, which disrupts membrane potential and inhibits mycobacterial fatty acid synthase (FAS-1).
300 mg orally once daily in combination with other antimycobacterial agents.
15-30 mg/kg orally once daily (max 2 g/day) for initial phase of tuberculosis treatment.
None Documented
None Documented
Terminal elimination half-life ranges from 8 to 70 days (mean approximately 14 days) due to extensive tissue storage and slow release; may be longer with chronic dosing.
Clinical Note
moderatePyrazinamide + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Pyrazinamide."
Clinical Note
moderatePyrazinamide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Pyrazinamide."
Clinical Note
moderatePyrazinamide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Pyrazinamide."
Clinical Note
moderatePyrazinamide + Fluconazole
9–10 hours in patients with normal renal function; prolonged to 15–20 hours in renal impairment; requires dose adjustment in renal failure
Primarily fecal (unabsorbed drug and biliary excretion); renal excretion accounts for <1% of the dose as unchanged drug and metabolites.
Renal: approximately 70% (40% unchanged, 30% as metabolites); biliary/fecal: minimal (less than 10%)
Category C
Category A/B
Antimycobacterial
Antimycobacterial
"The metabolism of Fluconazole can be decreased when combined with Pyrazinamide."